Mitsubishi Tanabe Pharma America
Xiomara Prats has extensive work experience in the pharmaceutical and healthcare industry. Xiomara is currently employed as a Regional Business Director SE at Mitsubishi Tanabe Pharma America since 2017. Before that, they worked as a Regional Director, Oncology - FL, GA, PR at bioTheranostics from 2016 to 2017, where they were responsible for building a team and promoting biomarker products for breast cancer and cancer diagnosis. Prior to that, they served as an Area Sales Manager, Oncology at Myriad Genetics from 2014 to 2016 and as a Division Sales Manager, Florida at Dendreon Corporation from 2012 to 2014. Xiomara Prats also gained valuable experience at Astellas Pharma, where they held various positions including Senior Manager, Oncology Sales Training- Acting Director from 2004 to 2012, Manager, Corporate Training and Leadership Development from 2007 to 2010, and Sales Specialist from 2004 to 2007. Their career started at Hoffmann-La Roche as a Hospital Representative and Virology Specialist from 1998 to 2004.
Xiomara Prats attended the University of Miami Herbert Business School from 1985 to 1988, where they obtained a Bachelor of Business Administration (BBA) degree with a focus on Marketing and Finance. Xiomara also pursued further education at the same institution, completing a Master of Business Administration (MBA) degree in Marketing and Finance from 1983 to 1988.
This person is not in the org chart
This person is not in any offices
Mitsubishi Tanabe Pharma America
We are taking on the challenges of complex and debilitating conditions and are committed to meeting the needs of people suffering from serious and often life-threatening illnesses. Today, we are focused on driving scientific discovery in many areas. Our focus remains on bringing treatment to people living with ALS as we strive to make a meaningful difference in their lives. Many people living with amyotrophic lateral sclerosis (ALS) have unmet medical needs. We are committed to doing our best to find solutions that may help address those needs. We continue to expand our work to deepen our understanding of ALS, explore potential biomarkers to aid in further research and seek new answers. Every day we tackle tough challenges in science and medicine. Our teams work diligently to develop smart options that will enable healthcare providers to offer safe and effective treatments for devastating illnesses. Please see our LinkedIn community guidelines here: http://www.mt-pharma-america.com/pdf/LinkedIn-Community-Guidelines.pdf